15 August 2019 - Gilead Sciences and Galapagos today announced that the marketing authorisation application for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis has been validated and is now under evaluation by the EMA.

The application for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievement of low disease activity and remission, and inhibition of structural damage for different sub-populations of patients living with rheumatoid arthritis. 

Across the FINCH program, safety data were consistent with previously reported results.

Read Gilead press release